



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/06 (2006.01)

A61P 35/00 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/EP2021/078516

(22) International Filing Date:

14 October 2021 (14.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2016386.1 15 October 2020 (15.10.2020) GB

2100737.2 20 January 2021 (20.01.2021) GB

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE).

(72) Inventors: **RAPECKI, Stephen Edward**; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **ADAMS, Ralph**; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **HUMPHREYS, David Paul**; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **FINNEY, Helen Margaret**; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

BITHELL, Rosemary Frances; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BINDING MOLECULES THAT MULTIMERISE CD45

Figure 1(A)





Figure 1(B)



(57) Abstract: The present invention provides binding molecule or molecules that are able to multimerise CD45 to induce cell death of a cell expressing CD45 without also inducing significant cytokine release. For example, the invention provides antibodies against CD45, wherein the antibodies comprise at least two different paratopes each specific for a different epitope of CD45. The antibodies may be used to cross-link CD45 on the surface of cells. The antibodies may be used in a variety of therapeutic ways including to deplete cells, for example prior to cell transplantation.

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*